Summary: Researchers unmasked the hidden mechanisms that allow the Ebola virus to survive undetected inside the human central nervous system for months or years. The international investigation utilized human induced pluripotent stem cells (iPSCs) to grow spherical, three-dimensional cerebral organoids.
The research team demonstrated that Ebola and related filoviruses (Sudan, Reston, and Marburg) achieve a state of “productive persistence” within human brain tissue. Rather than lying dormant, the virus continuously replicates inside neurons, astrocytes, and microglia for up to 120 days, generating defective viral genomes and driving chronic local inflammation that mimics the fatal meningoencephalitis seen in human survivors.
Key Facts
- The Reality of Productive Persistence: Traditional virology models often assume that long-term viral latency requires the pathogen to become completely inactive inside host cells. The BNITM team shattered this assumption, proving that Ebola maintains a “productive persistence” inside the brain, meaning it continuously generates new, fully infectious particles without burning out its host tissue.
- Dual Transmission Pathways: The data revealed that Ebola expands through the brain organoid using two distinct vectors. It deploys classical viral budding from the cell membrane to release free particles, while simultaneously utilizing direct cell-to-cell transmission to slip quietly between neighboring neurons, bypassing extracellular spaces.
- The Cytokine Inflammation Loop: Although immune-privileged tissues like the brain naturally suppress extreme immune reactions to protect sensitive architecture, the late-stage organoid cultures generated a massive surge of pro-inflammatory cytokines. This chronic, localized inflammatory state perfectly mirrors the severe eye, meningeal, and brain inflammation reported by human Ebola survivors months after clinical recovery.
- Defective Genomes as a Survival Shield: As the infection progressed into late stages, researchers identified an accumulation of specific genetic mutations and defective viral genomes. Because the virus lacks human proofreading machinery, it naturally generates these altered, attenuated particles to actively suppress its own replication velocity, keeping it just under the radar of complete host destruction.
- Replicating Real-World Human Mutations: Highlighting the translational power of the human organoid system, many of the genetic mutations discovered in the lab perfectly matched the viral genomes isolated from real-world human outbreaks. These specific mutations had been previously hypothesized to down-regulate viral replication in human patients, a theory this trial has formally validated.
- Replacing Vulnerable Animal Models: By executing these complex, long-term infection studies within a 100% human genetic background, the international coalition has opened up an immediate pathway to test and optimize next-generation antivirals. This human-centric approach provides a highly reliable screening platform while significantly reducing the scientific reliance on live animal testing in high-containment biosafety labs.
Source: DZIF
Following infection, the Ebola virus can survive unnoticed in the human body for months or even years, hiding in areas with little immune surveillance like the central nervous system. The danger is that those affected may have an Ebola virus disease relapse or even trigger a new outbreak.
Using a cerebral organoid model, researchers at the Bernhard Nocht Institute for Tropical Medicine (BNITM), the German Center for Infection Research (DZIF) and the Icahn School of Medicine at Mount Sinai (ISMMS), together with other collaborators, gained valuable insights into the mechanisms of such Ebola virus persistence.
The findings were recently published in Nature Microbiology.
Ebola virus is a filovirus that causes Ebola virus disease, which is a severe and often fatal infection. Even if those affected survive the acute phase of the disease, the virus can remain in the body. Infectious Ebola virus has been detected in semen for months or even a year after infection.
The virus can also persist in other immune-privileged organs such as the central nervous system, particularly the brain. Immune-privileged means that the immune system reacts in a weakened and controlled manner in these areas in order to protect sensitive tissue.
As a result, it cannot always eliminate the virus completely. This persistent viral presence increases the risk of late inflammatory disease and relapses in individual patients and, albeit rarely, of re-transmission to others.
Cerebral organoids suitable for investigating Ebola persistence
Little is known about the mechanisms that allow Ebola virus to survive long term in its host. Does it persist in tissues or in individual cells? Does it produce new infectious particles? Does it alter its genome to evade detection by our immune system? As research on the human central nervous system is highly complicated, suitable model systems are required instead.
This is precisely where the researchers focused their efforts. They successfully used an established cerebral organoid model to perform long-term infection studies. To make these organoids, they stimulated so-called human induced pluripotent stem cells in such a way that they developed into spherical, brain-like structures consisting of various cells of the central nervous system.
“These cerebral organoids enable us to investigate in detail the mechanisms that Ebola virus and other filoviruses use to persist in the human central nervous system. Through experiments in this model system, we can gain insights that help us improve our understanding of the long-term effects of persistence like the severe and sometimes fatal inflammation seen in Ebola virus disease survivors with meningoencephalitis,” explains Dr. Lina Widerspick, first author of the publication and former researcher at the BNITM.
She carried out part of the experiments during a research visit to the Integrated Research Facility (IRF)-Frederick of the National Institutes of Health (NIH) in the USA. She is now based at the Bundeswehr Institute of Microbiology in Munich.
Moreover, organoids give the unique opportunity to study this phenomenon in a human background rather than an animal model. This may help in re-assessing and optimising treatments like antivirals and further opens avenues to reduce the use of animal models in infectious disease research in the future.
Ebola virus can survive long-term in cerebral organoids
The researchers showed that Ebola virus and other filoviruses, such as Sudan, Reston and Marburg virus, can replicate in cerebral organoids for up to 120 days. They also found that Ebola virus infected various cell types in the cerebral organoids—neurons as well as astrocytes. Microglia, the brain’s immune cells, were also attracted to the site and infected by the virus.
Ebola virus was able to spread in the cerebral organoids in two ways: directly from an infected cell to a neighboring cell (cell-to-cell transmission) and by budding from the host cell, which is the classical way the virus spreads. Thus, this represents a ‘productive persistence’, meaning that Ebola virus is not present in an inactive state within cells, but remains infectious.
The cerebral organoids produced pro-inflammatory cytokines, but the immune response was unable to successfully eliminate the virus during the persistent infection.
“We observed elevated immune and inflammatory responses in the late stages of cerebral organoid culture. We therefore conclude that a persistent Ebola virus infection in immune-privileged tissues can lead to local inflammation. This observation is consistent with the fact that some Ebola virus disease survivors develop inflammation of the eye, meninges or brain months after infection with Ebola virus”, says Prof. César Muñoz-Fontela, head of the Virus Immunology research group at BNITM and co-last author of the study.
How Ebola adapts to survive
Defective viral genomes are considered a well-known mechanism used by many viruses to suppress their replication. This enables the viruses to survive in the body in an attenuated but long-lasting form. It is also known that the Ebola virus genomes mutate when they replicate for a long time, since their genetic machinery cannot proof-read the genomes as the human machinery would do.
The research team has now identified defective viral genomes and particles, and mutations in the Ebola virus genomes in late-stage persistently infected cerebral organoids.
“Many of these mutations had been proposed to reduce or prevent viral replication in naturally occurring infections. Because Ebola virus behaves similarly in this model system to how it does in human infections, this underscores the suitability of our cerebral organoids for investigating filovirus persistence,” explains Prof. Gustavo Palacios, expert on Ebola virus genomics, Professor of Microbiology at ISMMS in New York (USA) and co-last author of the publication.
The researchers also identified mutations that have not been described in Ebola virus disease survivors. Further investigations are now needed to determine whether these mutations are causally linked to filovirus persistence.
“Our work in human cerebral organoids highlights the potential of this model system to investigate persistent infections in immune-privileged tissues,” concludes Muñoz-Fontela.
“Further studies are now important to investigate the long-term interactions between virus and host, expanding our studies towards less-studied filoviruses like Reston, Taï Forest, Bombali, and Bundibugyo virus, and to deepen our understanding of filoviral persistence mechanisms,” says Muñoz-Fontela, who is also a scientist in the DZIF research area Emerging Infections.
Funding: In addition to BNITM, ISMMS, and IRF-Frederick/NIH, the research involved collaboration with investigators from the University Medical Center Hamburg-Eppendorf (UKE), the Leibniz Institute of Virology (LIV), and the Friedrich-Loeffler-Institut—the Federal Research Institute for Animal Health (FLI). Financial support was provided, among others, by the Collaborative Research Center (CRC) 1648 “Emerging Viruses: Pathogenesis, Structure, Immunity” of the German Research Foundation (DFG), the German Federal Institute for Risk Assessment (BfR), and DZIF.
Key Questions Answered:
A: By utilizing a brilliant survival strategy called productive persistence. The virus retreats into immune-privileged zones like the central nervous system, where the body naturally tones down its immune responses to prevent accidental damage to fragile brain cells. Once inside, Ebola uses its own replication mistakes to create defective, weakened versions of its genome. This intentional self-slowing keeps the virus from destroying the brain tissue outright, allowing it to simmer quietly under the radar.
A: A cerebral organoid is a miniature, three-dimensional model of the human brain grown in a laboratory from human stem cells. It contains real human neurons, astrocytes, and immune cells organized just like a natural brain. This human background is incredibly valuable because viruses behave differently in human tissue than they do in mice or monkeys. Using organoids gives scientists a flawless window into human-specific disease features while eliminating the ethical and logistical difficulties of animal testing.
A: They explain why many survivors suffer from severe, long-term neurological symptoms and identify the risk factors for sudden medical relapses. For months after beating the virus, survivors frequently experience chronic blindness, severe headaches, and life-threatening brain inflammation like meningoencephalitis. This study proves these symptoms are driven by a continuous, active viral presence in the brain that triggers localized inflammation, highlighting the urgent need for long-term antiviral monitoring and specialized care for survivors.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neurology and Ebola research news
Author: Press Office
Source: DZIF
Contact: Press Office – DZIF
Image: The image is credited to BNITM/Lina Widerspick
Original Research: Open access.
“Host–virus determinants of Ebola virus persistence in a human cerebral organoid model” by Lina Widerspick, Santiago Vidal Freire, Johanna F. Steffen, Shruti Shirsathe, Petra Allartz, Molly A. Vickers, Christoph Henkel, Pedro Neira Pelén, Julia Nave, Monika Rottstegge, Michelle Heung, Stephanie Wurr, Dennis Tappe, Lisa Oestereich, Jonas Müller, Angelique Hoelzemer, Leonore Mensching, Thomas Hoenen, Nicole C. Kleinstreuer, Ian Crozier, John G. Bernbaum, Gabriella Worwa, Jens H. Kuhn, Gustavo Palacios & César Muñoz-Fontela. Nature Microbiology
DOI:10.1038/s41564-026-02388-2
Abstract
Host–virus determinants of Ebola virus persistence in a human cerebral organoid model
Ebola virus (EBOV) causes Ebola virus disease (EVD), a multisystemic human disease associated with an extraordinarily high case-fatality rate. EVD survivors may experience recrudescent inflammation with viral persistence in immune-privileged tissues, including the central nervous system (CNS).
Persistence, defined by ongoing replication of the EBOV genome beyond the acute disease phase, may lead to virion production. Productive persistence has been linked to re-initiation of EVD outbreaks. We developed a human cerebral organoid model to investigate the host and viral determinants of EBOV CNS persistence. In this model, EBOV persistence for 120 days was sustained by continuous infection of astrocytes and neurons and the recruitment and infection of microglia.
This was accompanied by the emergence of EBOV defective viral genomes and genomic subvariants, cell-to-cell transmission, activation of cell-specific innate immunity, and late brain organoid inflammation, indicating that persistent infection of EBOV within immune-privileged niches drives local inflammation.
